ArticleScientific reports2025
In-silico study: Hm86 protein of Hyalomma marginatum (Ixodida) as a candidate to provide anti-tick vaccine.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Crimean-Congo hemorrhagic fever viral RNA-free hard ticks infesting livestock in a rural region of southern Iran.Parasite epidemiology and control · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Hyalomma marginatum is a major vector of Crimean-Congo hemorrhagic fever virus in Iran, posing serious threats to public health and livestock. With no effective vaccine currently available, recent studies have focused on identifying molecular targets for anti-tick vaccine development. This study investigates the HM86 protein through in-silico analysis to assess its potential as a vaccine candidate against H. marginatum. Hyalomma marginatum Hm86 protein was used to predict B-cell epitopes, assess sensitization, disulfide bond, physicochemical properties, allergenicity, and protein docking using online immunoinformatic servers. In silico analysis of the recombinant vaccine, based on an antigenic score of 0.7402, it was selected as a potential promising recombinant vaccine candidate. Docking was performed to determine the interaction between TLR2 and the Hm86 construct. The results indicated that the Hm86 gene possesses favorable immunogenic properties, is soluble, and effectively stimulates MHC class I pathways. Molecular docking between the modeled TLR2 receptor and the Hm86 protein revealed binding energies ranging from - 283.23 to - 242.95 kcal/mol and RMSD values between 81.50 and 96.50 Å. Notably, five residues of Hm86-B-GLU-172, B-TRP-144, B-ASN-174, B-THR-189, and B-THR-131-showed strong interactions with TLR2 through electrostatic forces, hydrophobic contacts, and multiple hydrogen bonds. These findings support the feasibility of Hm86 as an immunologically effective in-silico vaccine candidate for the control of H. marginatum.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.